Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world set...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/10/645 |
| _version_ | 1797574187343151104 |
|---|---|
| author | Yue (Jennifer) Du Rui Fu Justin T. Levinsky Pabiththa Kamalraj Kelvin K. W. Chan Ambica Parmar Antoine Eskander Martin Smoragiewicz |
| author_facet | Yue (Jennifer) Du Rui Fu Justin T. Levinsky Pabiththa Kamalraj Kelvin K. W. Chan Ambica Parmar Antoine Eskander Martin Smoragiewicz |
| author_sort | Yue (Jennifer) Du |
| collection | DOAJ |
| description | Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world setting. A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. The median patient age at nivolumab initiation was 61, 24% were female, and 62% were current or former smokers. Prior to nivolumab, 44% of patients underwent surgery, 97% radiation, and 100% chemotherapy. Most (97%) therapies were for primary disease. Overall survival at 6 and 12 months following drug initiation was 38% and 23%, respectively. Progression-free survival at 6 and 12 months was 33% and 22%, respectively. Eighteen percent of patients experienced an immune-related adverse event, the most common of which was pneumonitis (3/8) and endocrine events (3/8). Seven out of eight of the immune adverse events were grade 1–2; 1/8 was grade 3. Nivolumab appears to have decreased survival rates in our single-centre Canadian population compared to CHECKMATE-141 and presented a manageable adverse event profile for R/M HNSCC. |
| first_indexed | 2024-03-10T21:19:16Z |
| format | Article |
| id | doaj.art-1a7be7b7504d494daa77cb02299d0e67 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T21:19:16Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-1a7be7b7504d494daa77cb02299d0e672023-11-19T16:10:50ZengMDPI AGCurrent Oncology1198-00521718-77292023-09-0130108928893510.3390/curroncol30100645Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World ExperienceYue (Jennifer) Du0Rui Fu1Justin T. Levinsky2Pabiththa Kamalraj3Kelvin K. W. Chan4Ambica Parmar5Antoine Eskander6Martin Smoragiewicz7Temerty School of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaDepartment of Otolaryngology—Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDepartment of Otolaryngology—Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDepartment of Otolaryngology—Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDepartment of Otolaryngology—Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaNivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world setting. A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. The median patient age at nivolumab initiation was 61, 24% were female, and 62% were current or former smokers. Prior to nivolumab, 44% of patients underwent surgery, 97% radiation, and 100% chemotherapy. Most (97%) therapies were for primary disease. Overall survival at 6 and 12 months following drug initiation was 38% and 23%, respectively. Progression-free survival at 6 and 12 months was 33% and 22%, respectively. Eighteen percent of patients experienced an immune-related adverse event, the most common of which was pneumonitis (3/8) and endocrine events (3/8). Seven out of eight of the immune adverse events were grade 1–2; 1/8 was grade 3. Nivolumab appears to have decreased survival rates in our single-centre Canadian population compared to CHECKMATE-141 and presented a manageable adverse event profile for R/M HNSCC.https://www.mdpi.com/1718-7729/30/10/645nivolumabhead and necksquamous cell carcinomacancerchemotherapyPD-1 checkpoint inhibitor |
| spellingShingle | Yue (Jennifer) Du Rui Fu Justin T. Levinsky Pabiththa Kamalraj Kelvin K. W. Chan Ambica Parmar Antoine Eskander Martin Smoragiewicz Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience Current Oncology nivolumab head and neck squamous cell carcinoma cancer chemotherapy PD-1 checkpoint inhibitor |
| title | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
| title_full | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
| title_fullStr | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
| title_full_unstemmed | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
| title_short | Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience |
| title_sort | nivolumab for recurrent or metastatic head and neck squamous cell carcinoma a retrospective tertiary centre s real world experience |
| topic | nivolumab head and neck squamous cell carcinoma cancer chemotherapy PD-1 checkpoint inhibitor |
| url | https://www.mdpi.com/1718-7729/30/10/645 |
| work_keys_str_mv | AT yuejenniferdu nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT ruifu nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT justintlevinsky nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT pabiththakamalraj nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT kelvinkwchan nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT ambicaparmar nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT antoineeskander nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience AT martinsmoragiewicz nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience |